Introduction:

The COVID-19 pandemic severely affected humanity, causing high morbidity and mortality in all countries worldwide. The objective of this study was to determine the intensity and duration of IgG antibody response to the COVID-19 vaccine in healthcare workers.

Materials and methods:

A prospective descriptive longitudinal study was conducted to evaluate the immune response generated by a vaccine against COVID-19 by quantifying IgG antibodies to SARS -Cov-2. Measures were taken at 4, 8, and 12 months after vaccination.

Results:

In the first intake, 306 workers were studied, and the median of antibodies was 770.5 BAU/ml (IQR: 338.7-2314.2), in the second intake 169 workers with a median of 185.7 BAU/ml (IQR: 85.4-418.1), and in the third sample, 88 workers with a median of 3270 BAU/ml (IQR: 2480-3270). A higher antibody response rate was observed in workers with a history of COVID-19. There were no significant differences in antibody responses according to age, sex, job title, or workplace.

Discussion:

The COVID-19 vaccine generates a good antibody response, but this response decreases over time; therefore, booster doses are required. Quantitative RBD IgG antibody testing may be a good indicator of protection.

        · |     · |     · ( pdf )